Home

Mark J Alles

CIK 1538897 · CEO, CHAIRMAN OF BOARD · last filed 2023-09-19

Mark J Alles is a CEO, CHAIRMAN OF BOARD who has filed 71 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for SYRS, was dated Sep 19, 2023. Across all open-market trades the lifetime net is −$28.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $991.4K across reported positions. 56 SEC filings were submitted jointly with CELGENE CORP /DE/.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$991.4K

Companies

4

Total Filings

71

Lifetime Open-Market Net

-$28.07M

Filer Profile

Reported Address
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT, NJ 07901
Related Filers
CELGENE CORP /DE/ — 56 joint filings, latest 2019-11-22
BIOMARIN PHARMACEUTICAL INC — 5 joint filings, latest 2023-05-24
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Syros Pharmaceuticals, Inc. (SYRS) Delisted Director 3,666 $0.00 $1 $88.6K 8 2023-09-19
BMRN Director 15,095 $65.68 $991.4K $314.5K 4 2023-05-24
Turning Point Therapeutics, Inc. (TPTX) Delisted Director 0 $76.01 $0 $162.7K 4 2022-08-17
CELGENE CORP /DE/ (CELGZ) Delisted CEO, CHAIRMAN OF BOARD 292,081 — — -$28.64M 55 2019-11-22

Recent Filings

71 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-09-19 Syros Pharmaceuticals, Inc. (SYRS) Delisted Exer (M) +2,666 $0 EDGAR
2023-06-02 Syros Pharmaceuticals, Inc. (SYRS) Delisted Grant (A) — $0 EDGAR
2023-05-24 BMRN Grant (A) +4,190 $0 EDGAR
2022-11-02 BMRN Buy (P) +3,625 $314.5K EDGAR
2022-09-19 Syros Pharmaceuticals, Inc. (SYRS) Delisted Grant (A) — $0 EDGAR
2022-08-17 Turning Point Therapeutics, Inc. (TPTX) Delisted Disp (D) −2,000 -$152.0K EDGAR
2022-06-02 Syros Pharmaceuticals, Inc. (SYRS) Delisted Grant (A) — $0 EDGAR
2022-05-26 BMRN Grant (A) +4,980 $0 EDGAR
2022-01-05 BMRN Grant (A) +2,300 $0 EDGAR
2021-06-21 Turning Point Therapeutics, Inc. (TPTX) Delisted Buy (P) +2,000 $162.7K EDGAR
Showing 1–10 of 71
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.